Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as C$0.10 and last traded at C$0.08, with a volume of 155000 shares changing hands. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The company has a 50-day moving average of C$0.09 and a two-hundred day moving average of C$0.06. The stock has a market capitalization of C$7.41 million, a PE ratio of -4.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Ride Out The Recession With These Dividend Kings
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Investing in Construction Stocks
- 3 Penny Stocks Ready to Break Out in 2025
- Manufacturing Stocks Investing
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
